Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
NCT06475417
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
Interventions
DRUG:
Adebrelimab combined with DOS
Sponsor
Tang-Du Hospital
Collaborators
[object Object]